- Home
- CE vs IONS Comparison
CE vs IONS Comparison
Compare CE & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CE
- IONS
- Stock Information
- Founded
- CE 1918
- IONS 1989
- Country
- CE United States
- IONS United States
- Employees
- CE N/A
- IONS N/A
- Industry
- CE Major Chemicals
- IONS Biotechnology: Pharmaceutical Preparations
- Sector
- CE Industrials
- IONS Health Care
- Exchange
- CE Nasdaq
- IONS Nasdaq
- Market Cap
- CE 4.5B
- IONS 5.4B
- IPO Year
- CE 2005
- IONS 1991
- Fundamental
- Price
- CE $52.21
- IONS $32.99
- Analyst Decision
- CE Hold
- IONS Buy
- Analyst Count
- CE 18
- IONS 18
- Target Price
- CE $69.50
- IONS $57.41
- AVG Volume (30 Days)
- CE 3.0M
- IONS 1.5M
- Earning Date
- CE 05-05-2025
- IONS 04-30-2025
- Dividend Yield
- CE 0.23%
- IONS N/A
- EPS Growth
- CE N/A
- IONS N/A
- EPS
- CE N/A
- IONS N/A
- Revenue
- CE $10,058,000,000.00
- IONS $717,253,000.00
- Revenue This Year
- CE N/A
- IONS $7.16
- Revenue Next Year
- CE $3.48
- IONS $19.10
- P/E Ratio
- CE N/A
- IONS N/A
- Revenue Growth
- CE N/A
- IONS N/A
- 52 Week Low
- CE $36.29
- IONS $23.95
- 52 Week High
- CE $169.50
- IONS $52.34
- Technical
- Relative Strength Index (RSI)
- CE 59.75
- IONS 58.84
- Support Level
- CE $44.12
- IONS $31.66
- Resistance Level
- CE $57.91
- IONS $33.94
- Average True Range (ATR)
- CE 2.13
- IONS 1.35
- MACD
- CE 1.23
- IONS 0.20
- Stochastic Oscillator
- CE 62.79
- IONS 78.29
About CE Celanese Corporation
Celanese is one of the world's largest producers of acetic acid and its downstream derivative chemicals, which are used in various end markets, including coatings and adhesives. The company is also one of the largest producers of specialty polymers, which are used in the automotive, electronics, medical, building, and consumer end markets. The company also makes cellulose derivatives used in cigarette filters.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.